作者：
Sessa,C. [1]
;
Shapiro,G.I. [2]
;
Bhalla,K.N. [3]
;
Britten,C. [4]
;
Jacks,K.S. [5]
;
Mita,M. [6]
;
Papadimitrakopoulou,V. [7]
;
Pluard,T. [8]
;
Samuel,T.A. [9]
;
Akimov,M. [10]
;
Quadt,C. [11]
;
Fernandez-Ibarra,C. [12]
;
Lu,H. ;
Bailey,S. ;
Chica,S. ;
Banerji,U.
作者单位：
Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, Los Angeles, CA, United States
[1]
Drug Development Unit, Institute of Cancer Research, Royal Marsden Hospital, Sutton, United Kingdom
[2]
University of Kansas Cancer Center, Kansas City, KS, United States
[3]
Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
[4]
Cancer Therapy and Research Center, San Antonio, United States
[5]
MD Anderson Cancer Center, Houston, TX, United States
[6]
Washington University, St. Louis, MO, United States
[7]
Georgia Health Sciences University, Augusta, GA, United States
[8]
Instituto Oncologico Della Svizzera Italiana, Bellinzona, Switzerland
[9]
Nevada Cancer Institute, Las Vegas, NV, United States
[10]
Novartis Pharma AG, Basel, Switzerland
[11]
Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
[12]
发布时间
2013-12-19
换一批
